The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from GlobeNewswire (a Nasdaq OMX company)

Sabra Announces Closing of 7.125% Series A Cumulative Redeemable Preferred Stock

Thursday, March 21, 2013

Sabra Announces Closing of 7.125% Series A Cumulative Redeemable Preferred Stock13:08 EDT Thursday, March 21, 2013IRVINE, Calif., March 21, 2013 (GLOBE NEWSWIRE) -- Sabra Health Care REIT, Inc. ("Sabra" or the "Company") (Nasdaq:SBRA) today announced the closing of an underwritten public offering of 5,750,000 shares of 7.125% Series A Cumulative Redeemable Preferred Stock (the "Series A Preferred Stock") at a price of $25.00 per share, pursuant to an effective registration statement, for net proceeds of approximately $138.2 million after deducting underwriting discounts and other estimated offering expenses. The 5,750,000 shares of the Company's Series A Preferred Stock includes the underwriters' exercise in full on March 20, 2013 of their option to purchase up to an additional 750,000 shares of the Company's Series A Preferred Stock. The Series A Preferred Stock is expected to be admitted for trading on the NASDAQ Global Select Market under the symbol "SBRA PA" within 30 days of the date of closing. The Company intends to contribute the net proceeds from this offering to its operating partnership subsidiary, Sabra Health Care Limited Partnership, which will in turn apply the proceeds to repay borrowings outstanding on the Company's amended secured revolving credit facility. The remaining proceeds to the Company will be used to fund possible future acquisitions or for general corporate purposes. Jefferies LLC, Citigroup Global Markets Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated acted as joint book-running managers for the offering. Raymond James & Associates, Inc. and Stifel, Nicolaus & Company, Incorporated acted as co-managers. Sabra has filed a shelf registration statement on Form S-3 (including a prospectus) relating to the offering described above with the SEC, which registration statement was declared effective on October 31, 2011. The offering was made by means of the prospectus and a prospectus supplement Sabra filed with the SEC on March 15, 2013. You may obtain copies of these documents for free on the website of the SEC at www.sec.gov or by contacting Jefferies LLC at 520 Madison Avenue, New York, New York 10022; Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; Merrill Lynch, Pierce, Fenner & Smith Incorporated at One Bryant Park, New York, New York 10036; Raymond James & Associates, Inc. at 880 Carillon Parkway, St. Petersburg, Florida 33716; and Stifel, Nicolaus & Company, Incorporated at 501 N. Broadway, St. Louis, Missouri 63102. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. The offering may be made only by means of the prospectus relating to the proposed offering.ABOUT SABRA Sabra Health Care REIT, Inc. (Nasdaq:SBRA), a Maryland corporation, operates as a self-administered, self-managed real estate investment trust (a "REIT") that, through its subsidiaries, owns and invests in real estate serving the healthcare industry. Sabra leases properties to tenants and operators throughout the United States. As of March 11, 2013, Sabra's portfolio included 119 real estate properties held for investment and leased to operators/tenants under triple-net lease agreements (consisting of (i) 96 skilled nursing/post-acute facilities, (ii) 22 senior housing facilities, and (iii) one acute care hospital), three mortgage loan investments and two preferred equity investments. As of March 11, 2013, Sabra's real estate properties held for investment had a total of 12,382 licensed beds, or units, spread across 27 states.CONTACT: Investor & Media Inquiries: (949) 679-0410